Tirzepatide
Personalized online GLP-1 care and weight management shaped around your goals, metabolic health, and overall well-being in mind.
Dual-agonist approach
Medical provider oversight
Ongoing follow-up
Two receptors, not one
The practical effect is that you feel full sooner, stay full longer, and your body handles glucose more efficiently between meals. Most patients describe it as the constant background negotiation with food going quiet.
It is not a stimulant and not a fat burner. It changes appetite signalling, which is why it works only while you take it and why the plan around it matters as much as the molecule.
DUAL-HORMONE POWER
WHAT CLINICAL RESEARCH SHOWS
ONCE-A-WEEK DOSING
REDUCED CRAVINGS
Honestly, Over Time
Something feels different
The scale moves
Constipation is common – fiber and water matter more than people expect.
The steady stretch
Plateau and maintenance
How Treatment Usually Runs
| PHASE | WEEKS | TYPICAL | PURPOSE |
|---|---|---|---|
| Start | 1-4 | 2.5 mg weekly | Tolerance only . This dose is not expected to drive weight loss |
| First step up | 5-8 | 5 mg weekly | The first therapeutic dose . Most people notice appetite change here |
| Build | 9-16 | 7.5-10 mg weekly | Increases continue only if side effects stay manageable |
| Maintenance | 17+ | 10-15 mg weekly | Held at the lowest dose that keeps progress steady |
What the
Research Shows
Your Peptide Therapy
Questions
In the SURMOUNT-1 trial of Zepbound® (tirzepatide), adults with obesity lost an average of about 20% of total body weight at the highest dose over 72 weeks. Individual results vary widely and depend on dose, adherence, diet, activity and medical history.
In comparable trials, Tirzepatide produced greater average weight reduction. It is not automatically the better choice for you — tolerance, cost, availability and medical history all factor into what your provider recommends.
Most patients notice reduced appetite within one to two weeks of the first therapeutic dose. Measurable weight change typically appears between week four and week eight and continues as the dose titrates upward.
Nausea, constipation, diarrhoea, fatigue and injection-site reactions. They are most pronounced in the days following a dose increase and usually ease as your body adjusts. Severe persistent abdominal pain requires immediate medical attention.
Not necessarily, but appetite typically returns to baseline after stopping and weight regain is common without a maintenance plan. Your provider will discuss tapering, maintenance dosing and lifestyle strategy before you stop.
Every prescription is written by a licensed provider after a live visit and dispensed by a licensed pharmacy. Your provider prescribes only when it is clinically appropriate for you, orders bloodwork when your treatment calls for it, and reviews you on an ongoing basis.
Often Part of the Same Plan
